In addition, another study showed that massively parallel sequencing coupled with dose-adjusted gemcitabine/carboplatin treatment of metastatic cancers with mutations in PDGFRA, SMAD4, and CDKN2A may lead to improved outcome46. This evidence concerns the gene CDKN2A and metastatic malignant neoplasm.